Streptozocin is an anti-tumor agent commonly used in metastatic cancer of pancreatic islet cells. Streptozocin is freely soluble in aqueous solution (>100 mg/mL).
| Mechanism of Action | Streptozocin acts as an alkylating agent which damages DNA by adding methyl and other alkyl groups which interfere with normal base pairing. |
| Impurity Profile | α-isomer: ≥75.0% Residue on Ignition: ≤0.1% Heavy Metals: ≤20ppm |
| Eukaryotic Cell Culture Applications | Streptozocin is frequently used to induce diabetes and insulitis for diabetes research in mamalian models. Streptozocin (TOKU-E) was used in a study by Xufeng et al. : Effects of Radix linderae extracts on a mouse model of diabetic bladder dysfunction in later decompensated phase |
| Cancer Applications | Streptozocin has shown to decrease tumor size and relevant tumor-induced symptoms including hypoglycemia. |
| Molecular Formula | C8H15N3O7 |
| References | Murray-Lyon IM et al (1968). Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 2 (7574): 895–898 Broder LE and Carter SK (1973) Pancreatic islet cell carcinoma. II. Results of therapy with Streptozotocin in 52 patients. Ann. Intern. Med 179:108–118 Moertel CG, Hanley JA and Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma . N Eng. J Med 303:1189–1194 |
